The Medtronic  Foundation is making an additional $10 million in contributions to COVID-19 relief efforts around the world. The Fridley, Minn.-based company spokesman said that the funds will be put toward training and supervising frontline health workers, ensuring their safety (including the provision of personal protective equipmonprofit partners working

       Geoff Martha, who leads Medtronic’s restorative therapies group and previously oversaw the company’s spine business, will succeed Omar Ishrak as president and CEO on April 27. Ishrak ‘s nearly 10-year tenure as chairman and CEO of Medtronic will come to an end when he retires April 26.

    Medtronic plc  and the Medtronic Foundation are committing approximately $1.2 million to coronavirus relief efforts across the globe. These contributions encompass Medtronic Foundation cash contributions and product donations from the company, according to an announcement Feb. 10.                Medtronic Foundation is partnering

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

After three years in the bundled joint replacement business, a federal policy shift is prompting Medtronic to put its Responsive Orthopedics business on the auction block. The May 2016 acquisition of Minneapolis-based Responsive for an undisclosed amount put Medtronic in line for a bundled joint replacement program piloted by the Centers for Medicare & Medicaid Services. The 5-year “Comprehensive

    By Larry Storer The great medical technology companies of our time start and develop in a variety of ways. Some start with a product or idea and built a market around it. Some start as spinoffs from existing successful companies. But Venclose started by determining the unmet needs

A December study in The Journal of the American Heart Association by Konstantinos Katsanos, MD, of Rion, Greece, et al, reported a higher risk of death after balloons and stents used to open vessels in the legs were coated with an anti-inflammatory chemo agent called paclitaxel. “Further investigations are urgently

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for Medtronic to initiate a single-arm study to evaluate the CoreValve Evolut TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial

  Medtronic plc data presented Nov. 12 reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease in the superficial femoral and popliteal arteries. The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the